touchENDOCRINOLOGY had the pleasure of talking with TOS President Prof Dan Bessesen (UCHealth, University of Colorado, Aurora, CO, USA) around this year’s ObesityWeek®, the key highlights and future Obesity Society activities to look forward to.
- Could you tell us a little about ObesityWeek® and its key themes for 2022? (0:21)
- What do you expect to be the highlights of the scientific programme? (2:01)
- What other activities can we look forward to from the Obesity Society in 2022? (3:41)
- What do you consider the key advances in obesity research in the last year? (5:46)
Disclosures: Dan Bessesen has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd.
Share this Video
Related Videos In Obesity
Osama Hamdy, ADA 2022: Phenotypes and target options in diabetes
The 82nd ADA meeting, June 3-7, 2022, hosted a debate surrounding targets for diabetes management being body weight or glycaemic control. Dr Osama Hamdy (Joslin Diabetes Center, Boston, MA, USA) discusses the array of phenotypes with which diabetes presents, with precision medicine being the ultimate goal. Questions: What were your highlights of this year’s meeting? […]
Osama Hamdy, ADA 2022: Tirzepatide for obesity in the SURMOUNT-1 study and remission in type 2 diabetes
The results of SURMOUNT-1, the first phase 3 trial with the novel GIP/GLP-1 receptor agonist tirzepatide for obesity, is discussed by Dr Osama Hamdy (Joslin Diabetes Center, Boston, MA, USA) as well as key data on remission, a key theme at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022. Questions: What were the […]
W Timothy Garvey, ADA 2022: Semaglutide for type 2 diabetes, the 10-year risk in patients with obesity
A risk stratification tool has been developed that enables the prediction of the 10-year risk of patients with obesity developing type 2 diabetes. Dr W Timothy Garvey (University of Alabama at Birmingham, Birmingham, AL, USA) discusses the tool, named Cardiometabolic Disease Scoring, the impact of semaglutide on the risk of developing type 2 diabetes and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!